Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB1 | P18505 | 1/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56959 | 1.00 | GABRB1 (0.56) | GABRB1GABRB2MAPTCTSKCTSS | |
| SCHEMBL1954379 | 1.00 | GABRB1 (0.56) | GABRB1GABRB2MAPTCTSKCTSS | |
| SCHEMBL31355000 | 0.89 | MMP13 (0.51) | GABRB1GABRB2MAPTCTSKCTSS | |
| SCHEMBL9607542 | 0.89 | GABRB1 (0.57) | GABRB1GABRB2MAPTCTSKCTSS | |
| SCHEMBL9607543 | 0.89 | GABRB1 (0.57) | GABRB1GABRB2MAPTCTSKCTSS | |
| SCHEMBL15289227 | 0.86 | MAPT (0.56) | GABRB1GABRB2MAPTCTSKCTSS | |
| SCHEMBL20721134 | 0.86 | GABRB1 (0.55) | GABRB1GABRB2MAPTCTSKCTSS | |
| SCHEMBL13051349 | 0.84 | MAPT (0.60) | GABRB1GABRB2MAPTCTSKCTSS | |
| SCHEMBL90008 | 0.84 | MAPT (0.57) | GABRB1GABRB2MAPTCTSKCTSS | |
| SCHEMBL90081 | 0.84 | MAPT (0.57) | GABRB1GABRB2MAPTCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900223-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9546168-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160311819-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
| US-9226922-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | US | disclosed |
| WO-2015094929-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2507210-B1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| EP-2507210-B1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-8394858-B2 | Cyclohexane derivatives and uses thereof | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | US | disclosed |
| WO-2011067306-A1 | CYCLOHEXANE DERIVATIVES AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-1968940-A1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | GABRB1 1609/4885GABRB2 2122/4885MAPT 1089/4885 |
| US-20160311819-A1 | ERK INHIBITORS | MAPK1, MAPK10, MAPK3 | GABRB1 3708/4885GABRB2 4081/4885MAPT 2274/4885 |
| US-20110136735-A1 | CYCLOHEXANE DERIVATIVES AND USES THEREOF | CYP3A5, CYP11B2, CNR2 | GABRB1 1126/4885GABRB2 1257/4885MAPT 3197/4885 |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAP3K20 | GABRB1 3020/4885GABRB2 3449/4885MAPT 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.